Human rhinovirus type 14 protease 3C can be successfully expressed and purified in E. coli, retaining its specific cleavage activity, which is abolished by a Cys146 to Ser mutation.
Answers are grounded in this paper and cite their sources.
Enables scalable production of functional viral protease for inhibitor screens; leaves open any clinical translation.
Human rhinovirus type 14 protease 3C was expressed as a soluble and active protein in Escherichia coli. The protease was purified by a cationic-exchange step followed by gel filtration on a TSK 3000 column. The final yield of purified protease was in the range 0.5-1.0 mg/l culture grown to A550 = 1.0. Sequence analysis revealed that greater than 90% of the N-terminal residues were methionine. The enzyme activity of the purified protease was measured by cleavage of a synthetic peptide representing a predicted Gln/Gly viral polyprotein cleavage site. A mutant protease (Cys146----Ser) was produced and purified in the same way. The yield of mutant protease 3C was approximately 150 micrograms/l from a culture grown to A550 = 1.0. This mutant protease 3C did not cleave the synthetic peptide substrate.
No takes yet. Share an insight, caveat, or question.
KNOTT et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: